The ‘molecular mail’ sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology (ASH) by researchers at Dana-Farber Cancer Institute. The findings may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma, the study … Continue reading Researchers use circulating RNA to provide multiple myeloma prognosis.